The global high flow oxygen therapy devices market is anticipated to witness moderate growth, rising from USD 1.3 billion in 2025 to USD 1.6 billion by 2035 at a CAGR of 2.1% over the forecast period. Revenue generated by these devices was approximately USD 1,369.8 million in 2024, reflecting stable demand driven by the increasing prevalence of chronic respiratory disorders, expanding geriatric populations, and growing global healthcare infrastructure.
Chronic respiratory conditions, particularly chronic obstructive pulmonary disease (COPD), pneumonia, and severe asthma, significantly contribute to market demand. The World Health Organization emphasizes that COPD remains the third-leading cause of global mortality, necessitating robust respiratory care solutions. High flow oxygen therapy devices are increasingly preferred in clinical settings due to their effectiveness in delivering heated and humidified oxygen, enhancing patient comfort, reducing respiratory effort, and potentially minimizing the reliance on invasive mechanical ventilation, especially crucial during health emergencies and pandemics.
Technological innovation continues to define market competitiveness. Major manufacturers such as Fisher & Paykel Healthcare, Vapotherm, and ResMed are developing advanced devices with integrated pulse oximetry, wireless monitoring, and AI-driven oxygen management capabilities. These innovations enhance operational efficiency, accuracy, and patient outcomes.
Highlighting the industry’s focus on innovation and user-centric design, Bryan Liu, PhD, CEO of Telesair, emphasized the recent FDA-cleared Bonhawa system, stating, “The best-in-class Bonhawa system greatly improves patient care while enhancing efficiency for clinicians. It represents a significant milestone in that it is a more cost-effective, user-friendly option for treating respiratory conditions.” Such innovations underscore market commitment toward accessible and advanced respiratory solutions.
Global High Flow Oxygen Therapy Devices Industry Analysis
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 1.3 billion |
| Industry Value (2035F) | USD 1.6 billion |
| CAGR (2025 to 2035) | 2.1% |
North America and Europe currently dominate due to sophisticated healthcare infrastructure, favorable reimbursement policies, and increasing investments in respiratory preparedness. Asia Pacific, driven by improving healthcare access, rising disposable incomes, and expanding healthcare expenditures, particularly in China, India, and ASEAN nations, is emerging as a high-potential growth region. Steady epidemiological drivers, strategic innovations by leading manufacturers, supportive regulatory frameworks, and ongoing healthcare infrastructure enhancements collectively position the high flow oxygen therapy devices market for stable and sustained growth through 2035.
The following table shows the expected CAGR of the global high flow oxygen therapy devices market in several semi-annual periods across the years from 2025 to 2035. Business is expected to grow at 2.0% CAGR in the first half (H1) of the decade across the years 2024 and 2035, while there is a somewhat higher growth of 2.5% during the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 2.0% (2024 to 2034) |
| H2 | 2.5% (2024 to 2034) |
| H1 | 2.1% (2025 to 2035) |
| H2 | 2.5% (2025 to 2035) |
For the subsequent period, H1 2025 to H2 2035, a decrease is observed in the CAGR from 2.1% in the former half to a moderate increase of 2.5% in the latter half. Thereby in H1, the market increased by 10.00 BPS and in H2, the increase was of 4.04 BPS.
In 2025, heated humidifiers are projected to dominate the HFOT devices market, accounting for 47.5% of the market share. Their prominence is attributed to their critical role in delivering warm and humidified oxygen, which significantly improves patient comfort by preventing mucosal dryness and reducing airway irritation. This is particularly beneficial for patients requiring high-flow oxygen therapy, as it minimizes complications such as nasal bleeding and enhances overall therapy adherence.
The integration of heated humidifiers in HFOT systems has been shown to lower the frequency of airway damage, thereby promoting better patient compliance and potentially reducing the need for invasive ventilation methods. The growing preference for non-invasive treatment modalities and the emphasis on patient comfort in critical care settings have further propelled the demand for heated humidifiers. Leading manufacturers, including Fisher & Paykel Healthcare and ResMed, continue to innovate in this space, focusing on developing advanced humidification technologies that cater to diverse patient needs.
Acute respiratory failure is anticipated to be the leading application segment for HFOT devices in 2025, commanding a substantial 81.8% market share. This dominance is due to the critical need for rapid and effective oxygen support in patients experiencing sudden respiratory distress, often resulting from conditions such as pneumonia, trauma, or exacerbations of chronic obstructive pulmonary disease (COPD).
High-flow oxygen therapy devices offer a non-invasive and efficient alternative to mechanical ventilation, delivering high concentrations of oxygen at controlled flow rates. This approach not only improves oxygenation but also reduces the necessity for intubation, thereby decreasing the risks associated with invasive procedures. The increasing prevalence of respiratory diseases and the demand for prompt interventions in emergency and critical care units have significantly boosted the adoption of HFOT devices for managing acute respiratory failure. Healthcare providers are increasingly recognizing the benefits of HFOT in enhancing patient outcomes and optimizing resource utilization in critical care settings.
One of the principal drivers of the High Flow Oxygen Therapy (HFOT) Devices market is rising focus on non-invasive respiratory care.
The other driving factor for the HFOT Devices Market is the growing focus on non-invasive respiratory support. The health care providers have shifted their preference to treatments that are less invasive and comfortable for patients. This is perfectly what HFOT delivers because it is different from mechanical ventilation; in this case, intubation is not required, and therefore complications such as infection, injury, and longer recovery are minimized.
High-flow oxygen delivery is very well tolerated because this system uses high-flow oxygen supplied through a nasal cannula-a far more pleasant route for oxygenation compared with masks or intubation in the invasive technique. Noninvasive delivery obviates major complications of invasion, including ventilation-associated pneumonia. As such, the patients also tend to support the therapy quite well, providing an opportunity toward improved outcomes as well as swift recovery.
HFOT is extremely effective when used on patients, especially those with acute respiratory failure, COPD, and pneumonia, for whom the usual provision of mechanical ventilation is not generally necessary. The device can provide high levels of oxygen without discomfort along with sufficient airway pressure to achieve the client's desired goals.
Clinical evidence supporting the effectiveness of High Flow Oxygen Therapy (HFOT) is a powerful driver of growth in the HFOT devices market
The main driver of growth in the HFOT devices market is the clinical evidence that supports the fact that High Flow Oxygen Therapy is effective. Clinical trials and studies have all over proven the efficacy of HFOT on patient outcomes, particularly with patients diagnosed with respiratory failure or other severe forms of respiratory problems.
HFOT has been shown in studies to reduce the need for invasive intubation, which in itself usually carries complications such as infection with prolonged recovery and increased healthcare expenses. High-flow oxygen via a nasal cannula accounts for homogeneous oxygen levels, allowing for easier patient breathing.
In addition, the therapy has been reported to relieve some discomforts for patients by reducing discomfort caused by direct oxygen administration via methods such as masks or invasive mechanical ventilation. With this, the patients will be more compliant with heightened comfort, and they will recover fast since they are stressed and cannot tolerate extended treatments.
That the benefits of HFOT are now recognized by healthcare providers, such as its ability to avoid complications arising out of intubation and positive contribution it brings to the rate of recovery, thereby making HFOT increasingly popular as a standard treatment for various respiratory conditions. Growing clinical evidence coupled with better patient outcomes has made healthcare systems integrate HFOT in routine care.
The increasing demand for portable HFOT devices will prove to be a significant opportunity for manufacturing
There is an excellent market opportunity here for manufacturers because of the high demand for portable HFOT, especially because a greater number of patients suffering from chronic respiratory disease are seeking their treatment at home. Advanced technology has brought about a trend wherein HFOT devices are being developed as light-weight, efficient units with long battery life. These innovations make the devices more portable and convenient for patients for them to enjoy high quality oxygen therapy comfort in their own homes.
Through this, manufacturers would be able to reduce the amount of hospital-based treatments with the compact, user-friendly, and efficient portable HFOT devices as it will facilitate patients to take care of conditions such as COPD, asthma, and sleep apnea at home. In fact, most patients prefer their treatment options or healthcare systems' efforts to diminish admissions and, therefore, all the costs, to be as flexible, minimally invasive as possible, as well as being more personal and less institutional.
Manufacturers can achieve the growing demand for homecare solutions by focusing on the portability of HFOT devices. These instruments could be equipped with features such as flow rate adjustment, easy controls, and lightweight to make them more manageable for a patient or caregiver. Continuous oxygen therapy at home would enhance the comfort of the patients, and treatment systems would lighten the hospitals' load.
This movement creates an opportunity for product manufacturers to innovate customized products for home care, thereby penetrating a larger market space and becoming an important stakeholder in this growing trend.
The key constraint for the expansion of the High Flow Oxygen Therapy (HFOT) devices market is competition from alternative respiratory therapies.
The second type of respiratory treatments is another harsh restraint to the expansion of High Flow Oxygen Therapy (HFOT) devices' market. As much as advantages of HFOT include the ability to provide better oxygenation without intubation, this only serves to overlook the already centralized position of therapy such as CPAP and NIV that will continue to serve as major therapy for respiratory illness.
CPAP and NIV are highly accepted and market established for the conditions like sleep apnea, COPD, and acute respiratory distress. The therapies are usually cheaper, with a greater acceptance by the health care providers and have a longer clinical experience. In contrast, HFOT devices are expensive, with their technology and specialized features, thus making them inaccessible in resource-constrained settings.
The cost-effectiveness and familiarity of CPAP and NIV devices create a strong market barrier for HFOT, as healthcare systems and patients may prefer these alternatives. The long history of clinical evidence supporting CPAP and NIV makes it harder for HFOT to position itself as a preferred treatment, despite its advantages. This competitive landscape limits the overall growth potential of HFOT devices, as both healthcare providers and patients may opt for more cost-effective and widely trusted options.
The worldwide high flow oxygen therapy devices market is expected to register a CAGR of 1.2% for the historical period of 2020-2024.The high flow oxygen therapy devices industry expanded positively as its value reached to USD 1,369.8 million in 2024 from USD 1,438.5 million in 2020.
The high flow oxygen therapy devices market has indicated to grow progressively from the previous years. Among major growth factors that have occurred to the market has been a boost in prevalence related to respiratory disorders and a strong requirement for the non-invasive treatment modality. Initially, HFOT devices were identified and found more primarily used within a hospital setting. In particular, especially during the COVID-19 pandemic, these devices have been largely used for acute respiratory distress management. This is because a safer alternative than mechanical ventilation exists in the form of HFOT.
The market is going to expand in the future as portable HFOT devices advance. These devices are becoming more and more accessible for homecare applications. Advances in battery-operated systems, simplicity of use, and remote monitoring will further spur adoption by chronic respiratory patients. Greater emphasis on patient care and attempts to reduce hospitalizations will also cause the market to grow.
With greater clinical evidence presenting the efficacy of HFOT, healthcare professionals will incorporate such equipment into the normal care process. This is because there is improved awareness, better technology, and accessibility to the healthcare facility; hence, the future for the devices market in HFOT seems to be in an upward progression and change in the following years.
Tier 1 firms consist of market leaders with a high market share of 64.8% in international market. These firms are involved in strategic alliances and acquisitions to increase their product offerings and gain access to advanced technologies. They also focus on large-scale clinical trials to confirm the safety and efficacy of their products. Prominent companies in tier 1 include Koninklijke Philips N.V., Fisher & Paykel Corporation Ltd.- , Resmed Corporation , Teleflex Corporation, Drägerwerk AG & Co. KGaA
Tier 2 companies include mid-size players having presence in specific regions and highly influencing the local market and holds around 14.8% market share. They typically pursue partnerships with academic institutions and research organizations to leverage emerging technologies and expedite product development. These companies often emphasize agility and adaptability, allowing them to quickly bring new treatments to market, additionally targeting specific types medical conditions. Additionally, they focus on cost-effective production methods to offer competitive pricing. Prominent companies in tier 2 include Vyaire Medical Inc., Vincent Medical (Inspired Medical), Hamilton Medical Inc., Eakin Healthcare Group Ltd ( Armstrong Medical) , Flexicare Medical , Besmed Health Business Corp, BMC Medical Co. Ltd. and others.
Finally, Tier 3 companies, such as Shenzhen Micomme Medical Technology, intersurgical Limited and Breas Medical AB. They specialize in specific products and cater to niche markets, adding diversity to the industry.
Overall, while Tier 1 companies are the primary drivers of the market, Tier 2 and 3 companies also make significant contributions, ensuring the high flow oxygen therapy devices sales remains dynamic and competitive.
The section below covers the industry analysis for the high flow oxygen therapy devices market for different countries. Market demand analysis of major countries in a number of regions of the world, such as North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe and Middle Ease & Africa, is presented. The United States is expected to lead in North America, with increased market share up to 2035. In South Asia & Pacific, India is expected to see a CAGR of 4.5% by 2035.
| Country | Value CAGR (2025 to 2035) |
|---|---|
| United States | 1.2% |
| Germany | 1.8% |
| Japan | 1.0% |
| China | 2.5% |
| India | 1.7% |
The United States high flow oxygen therapy devices market is anticipated to expand at 1.2% annualized rate between 2025-2035. It is already the largest in the North America marketplace.
Government and insurance assistance is crucial to the high growth of the USA high flow oxygen therapy devices market. Medicare reimbursement, Medicaid options, and private insurance schemes benefit patients in the USA for advanced therapies such as HFOT. This financial assistance allows greater access to treatment for a wider range of patients with chronic pulmonary disorders like COPD, asthma, and sleep apnea.
Reimbursement policy reduces the cost burden on both patients and healthcare providers. To this extent, HFOT devices are embraced widely as routine care. The less effort required from healthcare providers to embrace HFOT in treatment under the knowledge that it will be reimbursed by the insurer, the wider its application extends into hospitals, ambulatory settings, and home care. This assistance also encourages further development of the market by driving the evolution and widespread use of advanced HFOT devices, making them a standard technology for respiratory care in the United States.
China high flow oxygen therapy devices market has a rosy future with the anticipated CAGR of 2.5% in the years 2025-2035. It is presently leading in the East Asia market, which is anticipated to continue in the years to come, forecasted period.
Such chronic respiratory diseases include chronic obstructive pulmonary disease and asthma, and primarily relate to the ever-increasing levels of air pollution, smoking, and an aging population. Urbanization alone elicits huge pollution, thereby aggravating respiratory conditions, coupled with high smoking rates, despite public health intervention efforts. It has been noted that these chronic respiratory diseases include chronic obstructive pulmonary disease and asthma, which are linked with many factors like rising levels of air pollution, smoking, and an aged population.
Major pollution causing a respiratory problem has been due to urbanization, and the level of smoking has remained high even though public health interventions are ongoing, which causes respiratory ailments.
With these respiratory diseases on the rise, the health care system needs to provide a better treatment option to counteract this pressure. The non-invasive, high-precision solution offered by HFOT helps manage these conditions to ensure improved patient comfort and oxygen delivery. Advanced respiratory support that requires high numbers is needed to be used due to the large population of patients in China, hence, the uptake of HFOT as a standard therapy by the healthcare providers in managing respiratory failure to enhance patient outcomes has been on the rise, thus boosting the need for these devices in the country.
The Indian high flow oxygen therapy devices market is likely to grow at a CAGR of 1.7% from 2025 to 2035. Currently, it has the largest market share in the South Asia & Pacific region and is likely to follow this trend in the forecast period too.
As the country's middle class is on the increase, so also is the country's need for high-quality advanced medical care; thus, all the private healthcare facilities and medical centers opt to use the latest technology. The private health administrators are adopting HFOT systems due to the felt advantages that accompany conditions such as chronic obstructive pulmonary disease, asthma, and pneumonia.
The most apparent growth is within the private hospitals in urban cities that have the highest need for sophisticated medical solutions. To remain competitive, such hospitals will need to deliver the most up-to-date treatments like HFOT to provide better outcomes than conventional oxygen therapies and to position patients with greater comfort. This has resulted in increased private healthcare facilities and patients' willingness to pay extra for high-quality care. This has propelled the development of HFOT devices in the Indian market.
The players in the market are employing tactics to remain competitive, for example, product differentiation through innovative formulations, strategic alliances with health providers for distribution. Another prominent strategic emphasis of these firms is actively seeking strategic partners to strengthen their product lines and increase their international market presence.
Recent Industry Developments in High Flow Oxygen Therapy Devices Market
| Report Attributes | Details |
|---|---|
| Industry Size (2025) | USD 1.3 billion |
| Projected Industry Size (2035) | USD 1.6 billion |
| CAGR (2025 to 2035) | 2.1% |
| Base Year for Estimation | 2024 |
| Historical Period | 2019 to 2023 |
| Forecast Period | 2025 to 2035 |
| Quantitative Units | Revenue in USD billion |
| Product Types | High Flow Nasal Cannulas, High Flow Oxygen Masks, Breathing Circuits, Heated Humidifiers and Accessories |
| Applications | Pneumonia, Acute Respiratory Failure |
| End Users | Less than 100 Beds Hospitals, 100-250 Beds Hospitals, 250-500 Beds Hospitals, 500 Beds and Above Hospitals |
| Regions Covered | North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia, Middle East and Africa (MEA) |
| Key Players | Koninklijke Philips N.V., Fisher & Paykel Corporation Ltd., Resmed Corporation, Teleflex Corporation, Drägerwerk AG & Co. KGaA, Vyaire Medical Inc., Vincent Medical (Inspired Medical), Hamilton Medical Inc., Eakin Healthcare Group Ltd (Armstrong Medical), Flexicare Medical |
| Additional Attributes | Increased prevalence of chronic respiratory conditions, expansion of home-based healthcare, and preference for non-invasive oxygen therapy methods are contributing to steady demand. Technological advancements in flow regulation and humidification are expected to enhance patient outcomes and drive adoption. |
| Quantitative Units | USD billion for value; Thousand units for volume |
| Customization and Pricing | Customization and Pricing Available on Request |
The global high flow oxygen therapy devices market is projected to witness CAGR of 2.1% between 2025 and 2035.
The global high flow oxygen therapy devices industry stood at USD 1,369.8 million in 2024.
The global high flow oxygen therapy devices market is anticipated to reach USD 1.6 billion by 2035 end.
China is set to record the highest CAGR of 2.5% in the assessment period.
The key players operating in the global high flow oxygen therapy devices market include Koninklijke Philips N.V., Fisher & Paykel Corporation Ltd., Resmed Corporation, Teleflex Corporation, Drägerwerk AG & Co. KGaA, Vyaire Medical Inc., Vincent Medical (Inspired Medical), Hamilton Medical Inc., Eakin Healthcare Group Ltd (Armstrong Medical) , Flexicare Medical and others.
Explore Therapeutic Device Insights
High-flow Oxygen Therapy Devices Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
